Leerink Partners Maintains Sell Rating on Halozyme with $51 Price Target

Leerink Partners analyst David Risinger maintains a Sell rating on Halozyme with a price target of $51.00. The analyst consensus is a Moderate Buy with an average price target of $68.10. The company reported a quarterly revenue of $325.72 million and a net profit of $165.16 million in its latest earnings release. Risinger is a 5-star analyst with a 53.96% success rate and an average return of 8.7%.

Halozyme Therapeutics Inc (HALO) has seen a mixed response from analysts following its Q2 2025 earnings report. The company reported quarterly revenue of $325.72 million and a net profit of $165.16 million, with earnings per share (EPS) of $1.54, exceeding analyst expectations [3].

Analysts from JMP Securities maintained a "Market Outperform" rating, raising the price target from $78.00 to $91.00, a 16.67% increase [1]. This decision comes as part of the latest reviews and adjustments by the analyst team at JMP Securities on August 6, 2025. Meanwhile, Citizens JMP also raised its price target to $91.00, maintaining a "Market Outperform" rating [2].

In contrast, Leerink Partners analyst David Risinger maintains a "Sell" rating with a price target of $51.00. Risinger, a 5-star analyst with a 53.96% success rate and an average return of 8.7%, cited concerns about the company's valuation and growth prospects [4].

The overall analyst consensus is a "Moderate Buy" with an average price target of $68.10. Based on the one-year price targets offered by 8 analysts, the average target price for Halozyme Therapeutics Inc (HALO) is $68.75, with a high estimate of $79.00 and a low estimate of $51.00 [1]. The average target implies an upside of 6.19% from the current price of $64.74.

Halozyme's strong financial performance is reflected in its impressive 25.65% revenue growth and robust current ratio of 8.39. The company's royalty revenue is projected to surpass $1 billion in 2026, with management highlighting several growth catalysts, including the approval of RYBREVANT subcutaneous in Europe and first-time approvals for Opdivo subcutaneous and VYVGART Hytrulo in CIDP in Europe [4].

However, the company's revenue figures for Q2 2025 fell short of expectations, with revenue of $206 million falling 27.97% short of the anticipated $286.01 million. Despite this, the company's strong royalty revenue growth and aggressive use of the share buy-back program have been highlighted by analysts as positive developments.

The company's operations are based in the United States, with minimal long-lived assets located internationally. Halozyme focuses on developing and commercializing novel oncology therapies, with a focus on human enzymes that alter tumors.

References:
[1] https://www.gurufocus.com/news/3040875/halo-jmp-securities-raises-price-target-despite-maintaining-market-outperform--halo-stock-news
[2] https://ca.investing.com/news/analyst-ratings/halozyme-therapeutics-stock-price-target-raised-to-91-by-citizens-jmp-93CH-4138899
[3] https://www.tradingview.com/news/reuters.com,2025:newsml_L8N3TX336:0-halozyme-therapeutics-inc-reports-results-for-the-quarter-ended-june-30-earnings-summary/
[4] https://seekingalpha.com/news/4479547-halozyme-raises-2025-revenue-guidance-to-1_355b-amid-accelerating-royalty-growth-and-new